Vincent Rajkumar, Professor of Medicine at the Mayo Clinic in Rochester and Editor‑in‑Chief at Blood Cancer Journal, shared on X:
“Twenty years after it was first approved for myeloma, lenalidomide is still very expensive: the 4th most drug in terms of Medicare Spend (in 2024).
$7.7 billion at approximately $100,000 per beneficiary per year.”
Other articles about lenalidomide on OncoDaily.